Skip to main content
Fig. 3 | Cancer & Metabolism

Fig. 3

From: Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Fig. 3

Changes in tumor response over dapagliflozin treatment. A Waterfall plot of percent change of RECIST 1.1 target measurements at end of treatment (EOT) using baseline as a reference identify 1 patient with progressive disease (PD), 9 patients with stable disease (SD), and 2 patients with partial response (PR). B CT scans for RECIST 1.1 target measurements were available for 11 of the 12 patients following EOT, identifying that the majority of patients (8/11) either developed new lesions at multiple timepoints (triangles) or experienced a > 30% increase in target lesion size. C With the exception of 1 patient, CA 19-9 decreased in all patients. CA19-9 was not detectable in patients 4 and 12 and not obtained at EOT for patient 11. D A positive correlation exists between CA 19-9 tumor marker expression and RECIST-based tumor measurements. Patients are uniformly color-coded across all panels

Back to article page